Natera, Inc.

NTRA Healthcare Diagnostics & Research

Natera, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 35.9% from fiscal 2024. In the quarter to June 2026, revenue grew 37.7%, EPS grew 36.5%, free cash flow fell 174.0% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.

391.98 12.81 −3.16%
Market cap
$58.4B
P/E
0.0×
Fwd P/E
−130×
Dividend yield
—
F-score
6/9
Altman Z
26.84
Beneish M
−2.17
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

0.00 0.00 0.00 0.00
P/S ratio
10.43 13.58 11.32 14.37
P/FCF ratio
208.20 287.05 270.78 461.93
P/Operating CF
371.85 423.90 704.46 709.82
P/B ratio
17.64 18.29 15.95 21.35
EV/Sales
10.11 13.27 11.03 14.10
EV/EBITDA
0.00 0.00 0.00 0.00
EV/FCF
201.83 280.55 263.88 453.32
Current Ratio
3.27 3.39 2.96 3.00
Net Debt/EBITDA
11.02 114.60 13.75 18.52
Debt/Equity
0.06 0.05 0.05 0.04
Earnings Yield
(1.42%) (0.67%) (0.82%) (0.50%)
Free Cash Flow Yield
0.48% 0.35% 0.37% 0.22%
Free Cash Flow per Share
0.27 0.28 0.13 (0.06)
Book value per Share
9.13 12.52 12.54 12.71
Free Cash Flow
36.98 37.82 18.03 (8.64)
EV/EBIT
0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates